Table 5 Overall survival analysis
Dichotomized variables | Associated level | OS | |
|---|---|---|---|
Hazard ratio (95% CI) | p-value | ||
Univariate analysis | |||
Age | > 66 years | 0.971 (0.514-1.834) | 0.9288 |
Sex | Male | 1.967 (1.033-3.748) | 0.0396 |
KPS | > 50 | 0.539 (0.283-1.029) | 0.0611 |
Histology | Adenocarcinoma | 0.965 (0.510-1.825) | 0.9118 |
Presence of liver metastasis | Yes | 0.982 (0.463-2.082) | 0.9616 |
Use of chemotherapy before hRT | Yes | 1.085 (0.572-2.057) | 0.8034 |
Time from first diagnosis to hRT | ≥ 12 months | 0.804 (0.424-1.524) | 0.5037 |
Other RT prior to hRT | Yes | 1.411 (0.656-3.034) | 0.3785 |
Use of any other hemostatic measure | Yes | 1.056 (0.409-2.724) | 0.9105 |
Bleeding cause | Primary tumor | 1.420 (0.623-3.236) | 0.4036 |
WHO bleeding score before hRT | Grade 3 | 1.380 (0.728-2.617) | 0.3239 |
Dose of hRT | < 30 Gy | 2.669 (1.286-5.540) | 0.0084 |
WHO bleeding score at end of hRT | Grade 2-4 | 5.882 (2.445-13.865) | <0.0001 |
WHO bleeding score at end of follow-up | Grade 2-4 | 2.006 (0.969-4.154) | 0.0609 |
Multivariate analysis | |||
Sex | Male | 1.007 (0.487-2.081) | 0.9859 |
Dose of hRT | < 30 Gy | 2.853 (1.360-5.987) | 0.0056 |
WHO bleeding score at end of hRT | Grade 2-4 | 6.456 (2.645-16.202) | <0.0001 |